Medicine (Austin & Northern Health) - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 10 of 21
  • Item
    No Preview Available
    Refining analyses of copy number variation identifies specific genes associated with developmental delay
    Coe, BP ; Witherspoon, K ; Rosenfeld, JA ; van Bon, BWM ; Vulto-van Silfhout, AT ; Bosco, P ; Friend, KL ; Baker, C ; Buono, S ; Vissers, LELM ; Schuurs-Hoeijmakers, JH ; Hoischen, A ; Pfundt, R ; Krumm, N ; Carvill, GL ; Li, D ; Amaral, D ; Brown, N ; Lockhart, PJ ; Scheffer, IE ; Alberti, A ; Shaw, M ; Pettinato, R ; Tervo, R ; de Leeuw, N ; Reijnders, MRF ; Torchia, BS ; Peeters, H ; O'Roak, BJ ; Fichera, M ; Hehir-Kwa, JY ; Shendure, J ; Mefford, HC ; Haan, E ; Gecz, J ; de Vries, BBA ; Romano, C ; Eichler, EE (NATURE PUBLISHING GROUP, 2014-10)
    Copy number variants (CNVs) are associated with many neurocognitive disorders; however, these events are typically large, and the underlying causative genes are unclear. We created an expanded CNV morbidity map from 29,085 children with developmental delay in comparison to 19,584 healthy controls, identifying 70 significant CNVs. We resequenced 26 candidate genes in 4,716 additional cases with developmental delay or autism and 2,193 controls. An integrated analysis of CNV and single-nucleotide variant (SNV) data pinpointed 10 genes enriched for putative loss of function. Follow-up of a subset of affected individuals identified new clinical subtypes of pediatric disease and the genes responsible for disease-associated CNVs. These genetic changes include haploinsufficiency of SETBP1 associated with intellectual disability and loss of expressive language and truncations of ZMYND11 in individuals with autism, aggression and complex neuropsychiatric features. This combined CNV and SNV approach facilitates the rapid discovery of new syndromes and genes involved in neuropsychiatric disease despite extensive genetic heterogeneity.
  • Item
    No Preview Available
    De novo mutations in epileptic encephalopathies
    Allen, AS ; Berkovic, SF ; Cossette, P ; Delanty, N ; Dlugos, D ; Eichler, EE ; Epstein, MP ; Glauser, T ; Goldstein, DB ; Han, Y ; Heinzen, EL ; Hitomi, Y ; Howell, KB ; Johnson, MR ; Kuzniecky, R ; Lowenstein, DH ; Lu, Y-F ; Madou, MRZ ; Marson, AG ; Mefford, HC ; Nieh, SE ; O'Brien, TJ ; Ottman, R ; Petrovski, S ; Poduri, A ; Ruzzo, EK ; Scheffer, IE ; Sherr, EH ; Yuskaitis, CJ ; Abou-Khalil, B ; Alldredge, BK ; Bautista, JF ; Berkovic, SF ; Boro, A ; Cascino, GD ; Consalvo, D ; Crumrine, P ; Devinsky, O ; Dlugos, D ; Epstein, MP ; Fiol, M ; Fountain, NB ; French, J ; Friedman, D ; Geller, EB ; Glauser, T ; Glynn, S ; Haut, SR ; Hayward, J ; Helmers, SL ; Joshi, S ; Kanner, A ; Kirsch, HE ; Knowlton, RC ; Kossoff, E ; Kuperman, R ; Kuzniecky, R ; Lowenstein, DH ; McGuire, SM ; Motika, PV ; Novotny, EJ ; Ottman, R ; Paolicchi, JM ; Parent, JM ; Park, K ; Poduri, A ; Scheffer, IE ; Shellhaas, RA ; Sherr, EH ; Shih, JJ ; Singh, R ; Sirven, J ; Smith, MC ; Sullivan, J ; Thio, LL ; Venkat, A ; Vining, EPG ; Von Allmen, GK ; Weisenberg, JL ; Widdess-Walsh, P ; Winawer, MR (NATURE PUBLISHING GROUP, 2013-09-12)
    Epileptic encephalopathies are a devastating group of severe childhood epilepsy disorders for which the cause is often unknown. Here we report a screen for de novo mutations in patients with two classical epileptic encephalopathies: infantile spasms (n = 149) and Lennox-Gastaut syndrome (n = 115). We sequenced the exomes of 264 probands, and their parents, and confirmed 329 de novo mutations. A likelihood analysis showed a significant excess of de novo mutations in the ∼4,000 genes that are the most intolerant to functional genetic variation in the human population (P = 2.9 × 10(-3)). Among these are GABRB3, with de novo mutations in four patients, and ALG13, with the same de novo mutation in two patients; both genes show clear statistical evidence of association with epileptic encephalopathy. Given the relevant site-specific mutation rates, the probabilities of these outcomes occurring by chance are P = 4.1 × 10(-10) and P = 7.8 × 10(-12), respectively. Other genes with de novo mutations in this cohort include CACNA1A, CHD2, FLNA, GABRA1, GRIN1, GRIN2B, HNRNPU, IQSEC2, MTOR and NEDD4L. Finally, we show that the de novo mutations observed are enriched in specific gene sets including genes regulated by the fragile X protein (P < 10(-8)), as has been reported previously for autism spectrum disorders.
  • Item
    Thumbnail Image
    Epilepsy, hippocampal sclerosis and febrile seizures linked by common genetic variation around SCN1A
    Kasperaviciute, D ; Catarino, CB ; Matarin, M ; Leu, C ; Novy, J ; Tostevin, A ; Leal, B ; Hessel, EVS ; Hallmann, K ; Hildebrand, MS ; Dahl, H-HM ; Ryten, M ; Trabzuni, D ; Ramasamy, A ; Alhusaini, S ; Doherty, CP ; Dorn, T ; Hansen, J ; Kraemer, G ; Steinhoff, BJ ; Zumsteg, D ; Duncan, S ; Kaelviaeinen, RK ; Eriksson, KJ ; Kantanen, A-M ; Pandolfo, M ; Gruber-Sedlmayr, U ; Schlachter, K ; Reinthaler, EM ; Stogmann, E ; Zimprich, F ; Theatre, E ; Smith, C ; O'Brien, TJ ; Tan, KM ; Petrovski, S ; Robbiano, A ; Paravidino, R ; Zara, F ; Striano, P ; Sperling, MR ; Buono, RJ ; Hakonarson, H ; Chaves, J ; Costa, PP ; Silva, BM ; da Silva, AM ; de Graan, PNE ; Koeleman, BPC ; Becker, A ; Schoch, S ; von Lehe, M ; Reif, PS ; Rosenow, F ; Becker, F ; Weber, Y ; Lerche, H ; Roessler, K ; Buchfelder, M ; Hamer, HM ; Kobow, K ; Coras, R ; Blumcke, I ; Scheffer, IE ; Berkovic, SF ; Weale, ME ; Delanty, N ; Depondt, C ; Cavalleri, GL ; Kunz, WS ; Sisodiya, SM (OXFORD UNIV PRESS, 2013-10)
    Epilepsy comprises several syndromes, amongst the most common being mesial temporal lobe epilepsy with hippocampal sclerosis. Seizures in mesial temporal lobe epilepsy with hippocampal sclerosis are typically drug-resistant, and mesial temporal lobe epilepsy with hippocampal sclerosis is frequently associated with important co-morbidities, mandating the search for better understanding and treatment. The cause of mesial temporal lobe epilepsy with hippocampal sclerosis is unknown, but there is an association with childhood febrile seizures. Several rarer epilepsies featuring febrile seizures are caused by mutations in SCN1A, which encodes a brain-expressed sodium channel subunit targeted by many anti-epileptic drugs. We undertook a genome-wide association study in 1018 people with mesial temporal lobe epilepsy with hippocampal sclerosis and 7552 control subjects, with validation in an independent sample set comprising 959 people with mesial temporal lobe epilepsy with hippocampal sclerosis and 3591 control subjects. To dissect out variants related to a history of febrile seizures, we tested cases with mesial temporal lobe epilepsy with hippocampal sclerosis with (overall n = 757) and without (overall n = 803) a history of febrile seizures. Meta-analysis revealed a genome-wide significant association for mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures at the sodium channel gene cluster on chromosome 2q24.3 [rs7587026, within an intron of the SCN1A gene, P = 3.36 × 10(-9), odds ratio (A) = 1.42, 95% confidence interval: 1.26-1.59]. In a cohort of 172 individuals with febrile seizures, who did not develop epilepsy during prospective follow-up to age 13 years, and 6456 controls, no association was found for rs7587026 and febrile seizures. These findings suggest SCN1A involvement in a common epilepsy syndrome, give new direction to biological understanding of mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures, and open avenues for investigation of prognostic factors and possible prevention of epilepsy in some children with febrile seizures.
  • Item
    Thumbnail Image
    A variant of KCC2 from patients with febrile seizures impairs neuronal Cl- extrusion and dendritic spine formation
    Puskarjov, M ; Seja, P ; Heron, SE ; Williams, TC ; Ahmad, F ; Iona, X ; Oliver, KL ; Grinton, BE ; Vutskits, L ; Scheffer, IE ; Petrou, S ; Blaesse, P ; Dibbens, LM ; Berkovic, SF ; Kaila, K (WILEY-BLACKWELL, 2014-06)
    Genetic variation in SLC12A5 which encodes KCC2, the neuron-specific cation-chloride cotransporter that is essential for hyperpolarizing GABAergic signaling and formation of cortical dendritic spines, has not been reported in human disease. Screening of SLC12A5 revealed a co-segregating variant (KCC2-R952H) in an Australian family with febrile seizures. We show that KCC2-R952H reduces neuronal Cl(-) extrusion and has a compromised ability to induce dendritic spines in vivo and in vitro. Biochemical analyses indicate a reduced surface expression of KCC2-R952H which likely contributes to the functional deficits. Our data suggest that KCC2-R952H is a bona fide susceptibility variant for febrile seizures.
  • Item
    Thumbnail Image
    Does variation in NIPA2 contribute to genetic generalized epilepsy?
    Hildebrand, MS ; Damiano, JA ; Mullen, SA ; Bellows, ST ; Scheffer, IE ; Berkovic, SF (SPRINGER, 2014-05)
  • Item
    No Preview Available
    Glucose metabolism transporters and epilepsy: Only GLUT1 has an established role
    Hildebrand, MS ; Damiano, JA ; Mullen, SA ; Bellows, ST ; Oliver, KL ; Dahl, H-HM ; Scheffer, IE ; Berkovic, SF (WILEY, 2014-02)
    The availability of glucose, and its glycolytic product lactate, for cerebral energy metabolism is regulated by specific brain transporters. Inadequate energy delivery leads to neurologic impairment. Haploinsufficiency of the glucose transporter GLUT1 causes a characteristic early onset encephalopathy, and has recently emerged as an important cause of a variety of childhood or later-onset generalized epilepsies and paroxysmal exercise-induced dyskinesia. We explored whether mutations in the genes encoding the other major glucose (GLUT3) or lactate (MCT1/2/3/4) transporters involved in cerebral energy metabolism also cause generalized epilepsies. A cohort of 119 cases with myoclonic astatic epilepsy or early onset absence epilepsy was screened for nucleotide variants in these five candidate genes. No epilepsy-causing mutations were identified, indicating that of the major energetic fuel transporters in the brain, only GLUT1 is clearly associated with generalized epilepsy.
  • Item
    No Preview Available
    Genetics of epilepsy The testimony of twins in the molecular era
    Vadlamudi, L ; Milne, RL ; Lawrence, K ; Heron, SE ; Eckhaus, J ; Keay, D ; Connellan, M ; Torn-Broers, Y ; Howell, RA ; Mulley, JC ; Scheffer, IE ; Dibbens, LM ; Hopper, JL ; Berkovic, SF (LIPPINCOTT WILLIAMS & WILKINS, 2014-09-16)
    OBJECTIVE: Analysis of twins with epilepsy to explore the genetic architecture of specific epilepsies, to evaluate the applicability of the 2010 International League Against Epilepsy (ILAE) organization of epilepsy syndromes, and to integrate molecular genetics with phenotypic analyses. METHODS: A total of 558 twin pairs suspected to have epilepsy were ascertained from twin registries (69%) or referral (31%). Casewise concordance estimates were calculated for epilepsy syndromes. Epilepsies were then grouped according to the 2010 ILAE organizational scheme. Molecular genetic information was utilized where applicable. RESULTS: Of 558 twin pairs, 418 had confirmed seizures. A total of 534 twin individuals were affected. There were higher twin concordance estimates for monozygotic (MZ) than for dizygotic (DZ) twins for idiopathic generalized epilepsies (MZ = 0.77; DZ = 0.35), genetic epilepsy with febrile seizures plus (MZ = 0.85; DZ = 0.25), and focal epilepsies (MZ = 0.40; DZ = 0.03). Utilizing the 2010 ILAE scheme, the twin data clearly demonstrated genetic influences in the syndromes designated as genetic. Of the 384 tested twin individuals, 10.9% had mutations of large effect in known epilepsy genes or carried validated susceptibility alleles. CONCLUSIONS: Twin studies confirm clear genetic influences for specific epilepsies. Analysis of the twin sample using the 2010 ILAE scheme strongly supported the validity of grouping the "genetic" syndromes together and shows this organizational scheme to be a more flexible and biologically meaningful system than previous classifications. Successful selected molecular testing applied to this cohort is the prelude to future large-scale next-generation sequencing of epilepsy research cohorts. Insights into genetic architecture provided by twin studies provide essential data for optimizing such approaches.
  • Item
    Thumbnail Image
    Clinical whole-genome sequencing in severe early-onset epilepsy reveals new genes and improves molecular diagnosis
    Martin, HC ; Kim, GE ; Pagnamenta, AT ; Murakami, Y ; Carvill, GL ; Meyer, E ; Copley, RR ; Rimmer, A ; Barcia, G ; Fleming, MR ; Kronengold, J ; Brown, MR ; Hudspith, KA ; Broxholme, J ; Kanapin, A ; Cazier, J-B ; Kinoshita, T ; Nabbout, R ; Bentley, D ; McVean, G ; Heavin, S ; Zaiwalla, Z ; McShane, T ; Mefford, HC ; Shears, D ; Stewart, H ; Kurian, MA ; Scheffer, IE ; Blair, E ; Donnelly, P ; Kaczmarek, LK ; Taylor, JC (OXFORD UNIV PRESS, 2014-06-15)
    In severe early-onset epilepsy, precise clinical and molecular genetic diagnosis is complex, as many metabolic and electro-physiological processes have been implicated in disease causation. The clinical phenotypes share many features such as complex seizure types and developmental delay. Molecular diagnosis has historically been confined to sequential testing of candidate genes known to be associated with specific sub-phenotypes, but the diagnostic yield of this approach can be low. We conducted whole-genome sequencing (WGS) on six patients with severe early-onset epilepsy who had previously been refractory to molecular diagnosis, and their parents. Four of these patients had a clinical diagnosis of Ohtahara Syndrome (OS) and two patients had severe non-syndromic early-onset epilepsy (NSEOE). In two OS cases, we found de novo non-synonymous mutations in the genes KCNQ2 and SCN2A. In a third OS case, WGS revealed paternal isodisomy for chromosome 9, leading to identification of the causal homozygous missense variant in KCNT1, which produced a substantial increase in potassium channel current. The fourth OS patient had a recessive mutation in PIGQ that led to exon skipping and defective glycophosphatidyl inositol biosynthesis. The two patients with NSEOE had likely pathogenic de novo mutations in CBL and CSNK1G1, respectively. Mutations in these genes were not found among 500 additional individuals with epilepsy. This work reveals two novel genes for OS, KCNT1 and PIGQ. It also uncovers unexpected genetic mechanisms and emphasizes the power of WGS as a clinical tool for making molecular diagnoses, particularly for highly heterogeneous disorders.
  • Item
    Thumbnail Image
    Harnessing Gene Expression Networks to Prioritize Candidate Epileptic Encephalopathy Genes
    Oliver, KL ; Lukic, V ; Thorne, NP ; Berkovic, SF ; Scheffer, IE ; Bahlo, M ; Zhou, F (PUBLIC LIBRARY SCIENCE, 2014-07-09)
    We apply a novel gene expression network analysis to a cohort of 182 recently reported candidate Epileptic Encephalopathy genes to identify those most likely to be true Epileptic Encephalopathy genes. These candidate genes were identified as having single variants of likely pathogenic significance discovered in a large-scale massively parallel sequencing study. Candidate Epileptic Encephalopathy genes were prioritized according to their co-expression with 29 known Epileptic Encephalopathy genes. We utilized developing brain and adult brain gene expression data from the Allen Human Brain Atlas (AHBA) and compared this to data from Celsius: a large, heterogeneous gene expression data warehouse. We show replicable prioritization results using these three independent gene expression resources, two of which are brain-specific, with small sample size, and the third derived from a heterogeneous collection of tissues with large sample size. Of the nineteen genes that we predicted with the highest likelihood to be true Epileptic Encephalopathy genes, two (GNAO1 and GRIN2B) have recently been independently reported and confirmed. We compare our results to those produced by an established in silico prioritization approach called Endeavour, and finally present gene expression networks for the known and candidate Epileptic Encephalopathy genes. This highlights sub-networks of gene expression, particularly in the network derived from the adult AHBA gene expression dataset. These networks give clues to the likely biological interactions between Epileptic Encephalopathy genes, potentially highlighting underlying mechanisms and avenues for therapeutic targets.
  • Item
    Thumbnail Image
    Mutations in Mammalian Target of Rapamycin Regulator DEPDC5 Cause Focal Epilepsy with Brain Malformations
    Scheffer, IE ; Heron, SE ; Regan, BM ; Mandelstam, S ; Crompton, DE ; Hodgson, BL ; Licchetta, L ; Provini, F ; Bisulli, F ; Vadlamudi, L ; Gecz, J ; Connelly, A ; Tinuper, P ; Ricos, MG ; Berkovic, SF ; Dibbens, LM (WILEY-BLACKWELL, 2014-05)
    We recently identified DEPDC5 as the gene for familial focal epilepsy with variable foci and found mutations in >10% of small families with nonlesional focal epilepsy. Here we show that DEPDC5 mutations are associated with both lesional and nonlesional epilepsies, even within the same family. DEPDC5-associated malformations include bottom-of-the-sulcus dysplasia (3 members from 2 families), and focal band heterotopia (1 individual). DEPDC5 negatively regulates the mammalian target of rapamycin (mTOR) pathway, which plays a key role in cell growth. The clinicoradiological phenotypes associated with DEPDC5 mutations share features with the archetypal mTORopathy, tuberous sclerosis, raising the possibility of therapies targeted to this pathway.